Celldex Therapeutics, Inc. CLDX announced today the presentation of
three-year survival data from the Phase 2 rindopepimut clinical program in
EGFRvIII-positive glioblastoma—a more aggressive form of glioblastoma
typically associated with reduced long-term survival in comparison to the
glioblastoma population as a whole. Across three Phase 2 studies of
rindopepimut, survival data remains consistent and suggests a substantial and
continuing survival benefit in comparison to independent control datasets (see
chart below) at the median and at three years. In the multi-center Phase 2 ACT
III study, the median overall survival is 24.6 months from diagnosis (21.8
months from study entry) and overall survival is 26% at three years. In the
Phase 2 ACT II study, the median overall survival is 24.4 months from
diagnosis (20.5 months from study entry) and overall survival is 23% at three
years. In the Phase 2 ACTIVATE study, the median overall survival is 24.6
months from diagnosis (20.4 months from study entry) and overall survival is
33% at three years.
Rindopepimut Overall Survival (OS) Across Three Phase 2 Studies in
EGFRvIII-Positive Glioblastoma vs Independent Control Datasets
Rindopepimut Phase 2 Studies (all data from study entry)
Median OS 3 years
(months)
ACT III (n=65) 21.8 26%
ACT II (n=22) 20.5 23%
ACTIVATE (n=18) 20.4 33%
Independent Control Datasets (all data from study entry)
MD Anderson EGFRvIII-positive patients
matched^1 to ACTIVATE patient population
(n=17) 12.2^2 6%
(contemporary with ACTIVATE)
Radiation Therapy Oncology Group (RTOG) 0525
study - all EGFRvIII-positive patients (n=142) 15.1 18%
(contemporary with ACT III)
RTOG 0525 study - all EGFRvIII-positive
patients treated with standard dose
temozolomide (n=62) 14.2 7%
(contemporary with ACT III)
RTOG 0525 study - EGFRvIII-positive patients
matched^1 to ACT III/IV patient population
(n=29) 16 13%
(contemporary with ACT III)
^1Controls are closely matched to rindopepimut patient criteria including
gross total resection of patient tumor and ~3 months without disease
progression at time of study entry; ^2In order to provide comparable
timeframes across datasets, data have been estimated assuming study entry at
three months from diagnosis.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in